STOCK TITAN
  1. Home
  2. Sec-filings
  3. GMED
  4. [144] GLOBUS MEDICAL INC SEC Filing

Globus Medical (NYSE: GMED) insider plans $2.2M sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

GLOBUS MEDICAL INC (GMED) received a Rule 144 notice for a proposed sale of restricted or control securities. A director, Stephen T. Zarrilli, plans to sell 25,000 shares of common stock through Raymond James & Associates on the NYSE, with an indicated aggregate value of $2,176,000.00. The shares are to be issued via a cashless option exercise with the issuer as of 08/18/2026.

Positive

  • None.

Negative

  • None.
Shares to be sold 25,000 shares Common stock to be sold under Rule 144 for the account of Stephen T. Zarrilli
Aggregate sale value $2,176,000.00 Indicated aggregate value of 25,000 common shares to be sold
Planned transaction date 08/18/2026 Date associated with the cashless option exercise and planned sale
Security identifier 134261914 Identifier listed for the common stock in the securities information section
Exchange NYSE Planned venue for sale of the 25,000 common shares
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
cashless option exercise financial
"Common | 08/18/2026 | Cashless Option Exercise | Issuer"
cashless exercise financial
"25000 | 08/18/2026 | Cashless Exercise"
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
attorney-in-fact regulatory
"as attorney-in-fact for Stephen Zarrilli"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What transaction did GLOBUS MEDICAL INC (GMED) disclose in this Rule 144 filing?
The filing discloses a planned sale of 25,000 shares of Globus Medical common stock under Rule 144 by director Stephen T. Zarrilli, to be executed through Raymond James & Associates on the NYSE on 08/18/2026.

What is the total indicated value of the GMED shares to be sold under this Rule 144 notice?
The planned sale covers shares with an aggregate indicated value of $2,176,000.00. This amount is based on the figures provided for the 25,000 common shares to be sold through Raymond James & Associates on the NYSE.

Who is the insider selling GLOBUS MEDICAL INC (GMED) shares and in what capacity?
The selling person is Stephen T. Zarrilli, identified as a director of Globus Medical Inc. The Rule 144 notice specifies that the shares are being sold for his account, with attorney-in-fact authority granted to Raymond James & Associates’ representative.

What is the nature of the GMED shares being sold in this Rule 144 filing?
The shares are common stock of Globus Medical Inc., to be obtained via a cashless option exercise from the issuer and then sold. The filing describes the transaction as a “Cashless Option Exercise” and “Cashless Exercise” dated 08/18/2026.

Which broker is handling the planned Rule 144 sale of GMED shares?
The planned sale will be handled by Raymond James & Associates, Inc., located at 880 Carillon Parkway, St. Petersburg, FL 33716. The shares are expected to be sold on the NYSE as stated in the Rule 144 disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR